Trends in generic prescribing and dispensing in Europe

Expert Review of Clinical Pharmacology

Volumn 1, Issue 4, 2008, Pages 497-503

  Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Biosimilar; Generic medicine; Generic substitution; Off patent market; Patient copayment; Pharmaceutical policy; Physician prescribing; Pricing; Reference pricing

Indexed keywords

ALLOPURINOL; AMOXICILLIN; ATENOLOL; CITALOPRAM; DICLOFENAC; ENALAPRIL; ERYTHROPOIETIN; GABAPENTIN; GENERIC DRUG; GRANULOCYTE COLONY STIMULATING FACTOR; INSULIN; INTERFERON; METFORMIN; OMEPRAZOLE; PAROXETINE; PRAVASTATIN; RAMIPRIL; RANITIDINE; SIMVASTATIN; TRAMADOL;

AMBULATORY CARE; ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; EUROPE; HUMAN; PATIENT; PHARMACIST; PRESCRIPTION;

EID: 49449090812     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.4.497     Document Type: Article

References (33)

1. Directive 2004/27/EC of the European Parliament and of the Council of 31st March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union L 136/34-57 (2004).
2. European Generic Medicines Association. Basic Notions of Generics. European Generic Medicines Association, Brussels, Belgium (2008).
3. Simoens S, De Coster S. Sustaining generic medicines markets in Europe. J. Generic Med. 3(4), 257-268 (2006).
4. Perry G. The European generic pharmaceutical market in review: 2006 and beyond. J. Generic Med. 4(1), 4-14 (2006).
5. European Generic Medicines Association. 2005 Market Review. The European Generic Pharmaceutical Markets. European Generic Medicines Association, Brussels, Belgium (2005).
6. IMS Health. Midas Database. IMS Health, London, UK (2005).
7. Class S. Whither generics? Why major restructuring lies ahead. J. Generic Med. 2(3), 1-8 (2005).
8. IMS Health. IMS Lifecycle R & D Focus. IMS Health, London, UK (2007).
9. Simoens S, De Bruyn K, Bogaert M, Laekeman G. Pharmaceutical policy regarding generic drugs in Belgium. Pharmacoeconomics 23(8), 755-766 (2005).
10. Filion KB, Delaney JAC, Brophy JM, Ernst P, Suissa S. The impact of over-the-counter simvastatin on the number of statin prescriptions in the United Kingdom: a view from the General Practice Research Database. Pharmacoepidemiolog. Drug Saf. 16(1), 1-4(2007).
11. Peny JM, Covilard JP. What is the value of authorised generic agreements? Assessments on the French market. J. Generic Med. 4(2), 106-116 (2007).
12. Schulz A. Evolving dynamics of US and European generics markets. J. Generic Med. 2(1), 23-32 (2004).
13. Danzon PM, Ketcham JD. Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, The Netherlands and New Zealand. NBER Working Paper no. 10007. National Bureau of Economic Research, Cambridge, MA, USA (2003).
14. Simoens S. International comparison of generic medicine prices. Curr. Med. Res. Opin. 23(11), 2647-2654 (2007).
15. Kanavos P, Taylor D. Pharmacy discounts on generic medicines in France: is there room for further efficiency savings? Curr. Med. Res. Opin. 23(10), 2467-2476 (2007).
16. Kanavos P. Do genetics offer significant savings to the UK National Health Service? Curr. Med. Res. Opin. 23(1), 105-116 (2007).
17. Schneeweiss S. Reference drug programs: effectiveness and policy implications. Health Policy 81(1), 17-28 (2007).
18. Le Pen C. Substitution Générique et Prescription dans le Répertoire [Generic Substitution and Prescribing Practices in the Off-patent Market]. University of Paris-Dauphine, Paris, France (2005).
19. Garattini L, Ghislandi S. Off-patent drugs in Italy. A short-sighted view? Eur. J. Health Econ. 7(1), 79-83 (2006).
20. Sturm H, Austvoll-Dahlgren A, Aaserud M et al. Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database Syst. Rev. 18(3), CD006731 (2007).
21. Gosden T, Torgerson DJ. The effect of fundholding on prescribing and referral costs: a review of the literature. Health Policy 40(2), 103-114 (1997).
22. Schreyögg J, Henke KD, Busse R. Managing Pharmaceutical Regulation in Germany - Overview and Economic Assessment. Discussion paper 2004/6. Technical University of Berlin, Berlin, Germany (2004).
23. Wilkin D, Coleman A, Dowling B, Smith K. The National Tracker Survey of Primary Care Groups and Trusts 2001/2002: Taking Responsibility? National Primary Care Research and Development Centre, Manchester and King's Fund, London, UK (2002).
24. Paris V. Pharmaceutical regulation in France 1980-2003. Int. J. Health Plann. Manage. 20(4), 307-328 (2005).
25. Willert PL. Assessment of the pharmaceutical market in Poland after accession to the European Union. Eur. J. Health Econ. 8(4), 347-357 (2007).
26. Karwal V. The changing competitive landscape in the global generics market: threat or opportunity? J. Generic Med. 3(4), 269-279 (2006).
27. Møller Pedersen K. Pricing and reimbursement of drugs in Denmark. Eur. J. Health Econ. 4(1), 60-65 (2003).
28. Rocchi F, Addis A, Martini N; Working Group of the National Drug Utilisation Monitoring Centre (OsMed). Current national initiatives about drug policies and cost control in Europe: the Italy example. J. Ambul. Care Manage. 27(2), 127-131 (2004).
29. Antoñanzas F, Oliva J, Pinillos M, Juàrez C. Economic aspects of the new Spanish laws on pharmaceutical preparations. Eur. J. Health Econ. 8(3), 297-300 (2007).
30. von der Schulenburg JMG. Management of cost and utilization of pharmaceuticals in Germany. Health Policy 41, S45-S53 (1997).
31. Gouveia Pinto C, Teixeira I. Pricing and reimbursement of pharmaceuticals in Portugal. Eur. J. Health Econ. 3(4), 267-270 (2002).
32. Brouwer WBF, Rutten FFH. Golden pill far pharmacists: generic prescription is barely cost-saving. Med Contact 57, 737-740 (2002).
33. Nowicki M. Basic facts about biosimilars. Kidney Blood Press. Res. 30(5), 267-272 (2007).